Financial Tearsheet
Company Overview
ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
Recent Financial News
IR Contacts
| LHA Investor Relations |
|
Yvonne Briggs |
Stock Performance
| Stock Fundamentals | Value |
|---|---|
| Today's Open | 1.80 |
| Volume | 236,222 |
| Day Range | 1.70 - 1.81 |
| 52 Week Range | 0.65 - 3.10 |
| Bid/Ask | 1.76 / 1.81 |
| Bid/Ask Size | 200 X 2,000 |
| Previous Close | 1.79 |
| Market Cap | 75.76 million |
| Shares Outstanding | 41.86 million |
| Dividend/Yield | 0.00 / 0.00% |
| EPS (TTM) | -0.359100 |
| P/E Ratio (TTM) | N/A |
